October 2026 CLFS Update: What Labs Need to Know About the New PLA Codes
Short answer: CMS's October 2026 Clinical Laboratory Fee Schedule update, Change Request 14569, adds 39 proprietary laboratory analysis codes, 0660U through 0698U, plus one waived-test code, and deletes three codes. It is effective October 1, 2026, with implementation on October 5. New PLA codes are contractor-priced until nationally priced.
What changed in the October 2026 CLFS quarterly update?
On August 24, 2026, CMS issued Transmittal R13884CP, which carries Change Request 14569, the October 2026 quarterly update to the Clinical Laboratory Fee Schedule and Clinical Laboratory Improvement Amendments (CLIA) edits. CMS followed with the provider education article MM14569 on August 25, 2026. The transmittal sets an effective date of October 1, 2026 and an implementation date of October 5, 2026.
The transmittal also changes how CMS packages the work. According to the document, CR 14569 merges three formerly separate recurring change requests: the quarterly CLFS update, the annual CLIA edits and new waived tests, and the quarterly CLIA edits and new waived tests. For billing teams, that means fee schedule changes and CLIA edit changes now arrive together in a single instruction.
On the code side, CR 14569 lists 40 new codes. Thirty-nine are in the 0660U-0698U range. The fortieth is 0442U with the QW modifier, a point-of-care assay from Lumos Diagnostics identified in the transmittal as FebriDx. Three codes are deleted effective October 1, 2026: 0556U, 0557U, and 0585U. The CMS file listing for the fourth-quarter release, 26CLABQ4, describes 2,243 records and states that it includes all changes identified in CR 14569.
How are the new PLA codes priced?
CMS adds the new codes to the national HCPCS file, so Medicare Administrative Contractors do not have to enter them manually. Pricing, however, does not arrive on day one. The transmittal states that new codes are contractor-priced where applicable until they are nationally priced, and that Medicare contractors price PLA codes only for laboratories within their jurisdiction.
That language has practical consequences. A lab that bills a new 0660U-0698U code in October should expect its MAC, not a national rate, to set the initial payment amount. Two labs in different MAC jurisdictions could see different treatment of comparable tests until the annual payment determination process sets a national rate. CR 14569 also includes a requirement that contractors locally price covered CLFS codes that are missing from the quarterly CLFS file or the Integrated Outpatient Code Editor until those codes appear.
The transmittal does not discuss gapfill or crosswalk methods for the new codes, so labs should not assume any particular pricing path from this document alone. For how national rates for molecular codes are set after the fact, see our review of preliminary CY 2027 CLFS rates for molecular pathology, and for how a lab obtains a PLA code in the first place, see our guide to the PLA code application deadline.
What do the deleted codes mean for claims?
The three deleted codes are 0556U, 0557U, and 0585U. The transmittal lists their abbreviated descriptors as NFCT DS P-S DNA&RNA 12 TRGTS, NFCT DS BV DNA MRK VAG FLUID, and TGSAP SO NEO CFDNA 521 GENES. Their delete date is October 1, 2026.
CMS tells contractors not to search their files to retract or retroactively pay claims because of these changes. Contractors adjust claims only when providers bring the issue to their attention. The practical reading for labs is that no automatic correction should be expected in either direction. A lab that billed a deleted code for a date of service on or after October 1 should review those claims itself, and a lab holding older claims should confirm the code was valid on the date of service. Our overview of genetic testing denials covers how to triage this kind of issue.
What are the CLIA rules for the new codes?
CR 14569 marks 0442U-QW as the only waived code in the update; every other new code is non-waived. Under the transmittal, a code marked non-waived requires a CLIA certificate of registration (type 9), compliance (type 1), or accreditation (type 3). Claims from facilities with no valid certificate, or with only a certificate of waiver (type 2) or a provider-performed microscopy certificate (type 4), must not be paid unless the claim carries the QW modifier. CMS notes that this does not replace earlier instructions allowing waiver and PPM laboratories to bill with QW.
For waived tests, codes marked as FDA-approved waived must carry the QW modifier for the contractor to recognize them as waived. One further requirement tells contractors not to reject claims that rely on FDA review decision summary documentation for listed codes. Labs that run both high-complexity molecular work and waived point-of-care tests under different certificates should confirm that each claim is routed with the right certificate number and modifier.
How does PAMA fit into this update?
CR 14569 includes a short PAMA section that molecular labs should read alongside the code lists. It cites Section 6226 of the Consolidated Appropriations Act, 2026, enacted February 3, 2026. For non-ADLT clinical diagnostic laboratory tests, the most recent reporting period ran from May 1, 2026 to July 31, 2026, based on a data collection period of January 1, 2025 to June 30, 2025. CMS states that no phased-in payment reduction applies in CY 2026, and that beginning January 1, 2027, payment for a test cannot decrease by more than 15% from the prior year's amount.
This is context, not a rate announcement. The October update does not publish new payment rates for the PLA codes. Labs modeling 2027 revenue should use the published CLFS files and the CMS preliminary rate materials, and treat the 15% limit as a ceiling on year-over-year decline, not a forecast.
What should lab billing teams do this month?
Begin by loading the Q4 CLFS file into your billing system and checking that each of the 39 new PLA codes and the three deletions are reflected. Compare the CLIA-waived indicator for every code you bill against your certificate types. Then look at your own test menu: if any of your tests map to 0660U-0698U, verify the code assignment, the descriptor, and the date of service rules with your MAC.
Next, check how your claim scrubber treats the three deleted codes, and flag any open claims that use them. Review the first October remittances for contractor-priced PLA lines, since the payment amount may be set locally. A coverage and coding check before submission reduces rework; our reference on ICD-10 codes for genetic testing and the guide to Medicare coverage for genetic testing are useful companions. The same week also brought the October 2026 lab NCD edit software update, so coordinate the two reviews. For workflows that check coverage criteria and coding before submission, explore the platform at ScreenMyGene.
Frequently asked questions
When do the new October 2026 CLFS codes take effect?
CMS lists October 1, 2026 as the effective date, generally by date of service, with an implementation date of October 5, 2026. The Q4 file, 26CLABQ4, carries 2,243 records and incorporates all changes identified in CR 14569, including the new PLA codes added to the national HCPCS file.
Which codes were deleted?
CMS deleted three codes effective October 1, 2026: 0556U, 0557U, and 0585U. Contractors will not search their files to retract or retroactively pay claims, but they will adjust claims that providers bring to their attention, so labs should self-audit any affected claims.
Who prices the new PLA codes?
New PLA codes are contractor-priced where applicable until they are nationally priced and complete the annual payment determination. CMS instructs MACs to price PLA codes only for laboratories within their own jurisdiction, so pricing can differ by MAC at first.
Does the QW modifier apply to the new codes?
Only 0442U is listed as CLIA waived, and it must carry QW. All other new codes are non-waived. Labs with only a waiver or provider-performed microscopy certificate are not paid for non-waived codes unless the claim uses QW, as earlier instructions allow.
How does the 2027 PAMA payment limit relate to this update?
CR 14569 restates that no phased-in reduction applies in CY 2026, and that beginning January 1, 2027 a test's payment cannot drop more than 15% from the prior year's amount. That limit comes from Section 6226 of the Consolidated Appropriations Act, 2026.
This article is educational and intended for laboratory and revenue cycle professionals. It is not legal, coding, or reimbursement advice, and it does not replace payer or CMS documents. Verify all code lists and instructions against current CMS publications before billing.
Sources: CMS Transmittal R13884CP (Change Request 14569), August 24, 2026; CMS MLN Matters MM14569, "Clinical Laboratory Fee Schedule and CLIA HCPCS Codes"; CMS CLFS Files, 26CLABQ4 (CY 2026 Q4 release); Consolidated Appropriations Act, 2026, Section 6226 as cited in CR 14569.